If female of childbearing potential, have a negative serum pregnancy test at screening and use a medically acceptable form of contraception starting at screening and continuing throughout the study (defined as an oral contraceptive, or barrier method combined with a spermicide)
Able to attend for regular clinic appointments
In opinion of investigator, the patient will be able to comply with the requirements of the protocol
Provide written informed consent.
You may not be if
Known hypersensitivity to or side effects relating to previous statin treatment, or current therapy which includes a statin, ezetimibe or fibrate
Clinically significant liver function abnormality; alcohol excess
Hypercholesterolaemia \> or equal to 6.5mmol/L
Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.
Any condition judged by investigator that would cause the study to be detrimental to patient.
Conditions: rheumatoid disease/other collagen vascular disease requiring therapy; diabetes mellitus; untreated hypothyroidism; inflammatory bowel disease; other respiratory disease; known alpha 1 antitrypsin deficiency; malignancy; documented history of ischaemic heart disease (IHD); cor pulmonale or known congestive heart failure; patients planning to undergo elective surgery during the study period.
Exacerbation in the last 4 weeks.
Significant hypoxia (PaO2 \<7.3kPa)
Known lactose intolerance.
Therapies: oral prednisolone for more than 1 week in the last 6 months; disease modifying drugs (Gold/ sulphasalazine etc); weight losing drugs; concomitant use of warfarin, cyclosporine; concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone). Use of any investigational drug within four weeks of the baseline visit.
Clareo Health | The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)
